Hyderabad: Dr. Reddy’s Laboratories has terminated its agreement with Novartis India for the distribution and promotion of select pharmaceutical brands in the country, following a change in the latter’s controlling shareholding.
The development was disclosed in a regulatory filing, where Dr Reddy’s stated that the agreement, originally signed on February 11, 2022, will now stand terminated. However, the company will continue to commercialise the products covered under the arrangement until September 30, 2026.
Agreement terms and termination details
Under the original agreement, Dr Reddy’s had been granted exclusive and non-transferable rights to promote, distribute and sell certain specified Novartis India products in the domestic market. The partnership enabled Dr Reddy’s to expand its portfolio by leveraging Novartis India’s established brands and therapeutic offerings.
The termination clause has been triggered due to a change in the controlling shareholding of Novartis India, although specific details regarding the ownership transition have not been disclosed by either company.
In a separate filing, Novartis India confirmed the development, stating that it will regain exclusive rights to market and distribute the products once the transition period concludes. The company also indicated that it will focus on securing market access and strengthening its presence for these brands independently.
No immediate financial impact disclosed
Both companies have clarified that no immediate financial implications arising from the termination have been disclosed at this stage. Additionally, neither party has revealed the exact list of brands covered under the agreement.
Novartis India has a diverse portfolio spanning multiple therapeutic areas, including pain management, calcium supplementation, gynaecology, neurosciences and transplant immunology. Some of its well-known brands include Voveran, Calcium Sandoz and Tegrital, which have a strong presence in the Indian pharmaceutical market.
Strategic shift for both companies
The termination of the agreement signals a strategic shift for both organisations. For Novartis India, regaining control over its product portfolio could allow greater flexibility in marketing, pricing and distribution strategies amid evolving market dynamics.
For Dr Reddy’s, the move may enable a sharper focus on its core business areas and pipeline, particularly in generics and specialty pharmaceuticals, both in India and globally.
The development comes at a time when the pharmaceutical sector is witnessing increased consolidation, regulatory scrutiny and competitive intensity, prompting companies to reassess partnerships and operational models.
Recent developments at Dr Reddy’s
Separately, Dr Reddy’s Laboratories has recently strengthened its global portfolio with the launch of a generic version of Sugammadex injection in the United States. The drug is used to reverse the effects of certain muscle relaxants administered during surgical procedures.
The company has introduced the injection in 200 mg/2 mL and 500 mg/5 mL single-dose vials. It is a generic equivalent of Bridion, a product originally developed by Merck Sharp & Dohme.
Conclusion
The termination of the agreement between Dr Reddy’s Laboratories and Novartis India marks the end of a significant commercial partnership shaped by changing ownership dynamics. While the transition period ensures continuity in the short term, both companies are expected to realign their strategies to strengthen their individual market positions in the coming years.